Evidence map›Paper›PMID 22931102›Full record

ArticleMolecular pharmaceutics2012

Pharmacokinetics and pharmacodynamics of phase II drug metabolizing/antioxidant enzymes gene response by anticancer agent sulforaphane in rat lymphocytes.

Hu Wang, Tin Oo Khor, Qian Yang, Ying Huang, Tien-Yuan Wu, Constance Lay-Lay Saw, Wen Lin, Ioannis P Androulakis, Ah-Ng Tony Kong

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.International journal of molecular sciences · 2020
    Review
  11. Article
  12. PERK activation mitigates tau pathologyEMBO molecular medicine · 2017
    Article
  13. Article
  14. The complexity of the Nrf2 pathway: beyond the antioxidant response.The Journal of nutritional biochemistry · 2015
    Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hu WangGraduate Program in Pharmaceutical Sciences, Department of Pharmaceutics, Ernest Mario School of Pharmacy, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Tin Oo Khor
Qian Yang
Ying Huang
Tien-Yuan Wu
Constance Lay-Lay Saw
Wen Lin
Ioannis P Androulakis
Ah-Ng Tony Kong
Rutgers, The State University of New Jersey · US

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
REGULATION OF PHASE 2 GENES BY ISOTHIOCYANATESR01CA073674 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KONG, AH-NG TONY · 1999 to 2012
$3.6M
Induction of Phase 2 Genes by Chemopreventive Agent BHAR01CA094828 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KONG, AH-NG TONY · 2001 to 2011
$2.9M
Epigenetic modifications by dietary PEITC in prostate cancerR01CA118947 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI KONG, AH-NG TONY · 2006 to 2015
$2.8M
NCI NIH HHS R01 CA073674NCI NIH HHS R01 CA094828NCI NIH HHS R01 CA118947NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

This study assesses the pharmacokinetics (PK) and pharmacodynamics (PD) of Nrf2-mediated increased expression of phase II drug metabolizing enzymes (DME) and antioxidant enzymes which represents an important component of cancer chemoprevention in rat lymphocytes following intravenous (iv) administration of an anticancer phytochemical sulforaphane (SFN). SFN was administered intravenously to four groups of male Sprague-Dawley JVC rats each group comprising four animals. Blood samples were drawn at selected time points. Plasma were obtained from half of each of the blood samples and analyzed using a validated LC-MS/MS method. Lymphocytes were collected from the remaining blood samples using Ficoll-Paque Plus centrifuge medium. Lymphocyte RNAs were extracted and converted to cDNA, quantitative real-time PCR analyses were performed, and fold changes were calculated against those at time zero for the relative expression of Nrf2-target genes of phase II DME/antioxidant enzymes. PK-PD modeling was conducted based on Jusko's indirect response model (IDR) using GastroPlus and bootstrap method. SFN plasma concentration declined biexponentially and the pharmacokinetic parameters were generated. Rat lymphocyte mRNA expression levels showed no change for GSTM1, SOD, NF-κB, UGT1A1, or UGT1A6. Moderate increases (2-5-fold) over the time zero were seen for HO-1, Nrf2, and NQO1, and significant increases (>5-fold) for GSTT1, GPx1, and Maf. PK-PD analyses using GastroPlus and the bootstrap method provided reasonable fitting for the PK and PD profiles and parameter estimates. Our present study shows that SFN could induce Nrf2-mediated phase II DME/antioxidant mRNA expression for NQO1, GSTT1, Nrf2, GPx, Maf, and HO-1 in rat lymphocytes after iv administration, suggesting that Nrf2-mediated mRNA expression in lymphocytes may serve as surrogate biomarkers. The PK-PD IDR model simultaneously linking the plasma concentrations of SFN and the PD response of lymphocyte mRNA expression is valuable for quantitating Nrf2-mediated effects of SFN. This study may provide a conceptual framework for future clinical PK-PD studies of dietary cancer chemopreventive agents in human.

Indexed as

Administration, IntravenousAnimalsAntineoplastic AgentsAntioxidantsIsothiocyanatesLymphocytesMaleMetabolic Detoxication, Phase IINF-E2-Related Factor 2RatsRats, Sprague-DawleyRNA, MessengerSulfoxidesThiocyanatesAntineoplastic AgentsAntioxidantsIsothiocyanatesNfe2l2 protein, ratNF-E2-Related Factor 2RNA, MessengersulforaphaneSulfoxidesThiocyanates

Identifiers

PMID22931102
PMCPMC3580178
OpenAlexW2093767448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.